Suppr超能文献

再照射生物标志物开发领域的进展:小型高效数据集与人工智能实用指南

Advances in the field of developing biomarkers for re-irradiation: a how-to guide to small, powerful data sets and artificial intelligence.

作者信息

Huma Chaudhry, Hawon Lee, Sarisha Jagasia, Erdal Tasci, Kevin Camphausen, Valentina Krauze Andra

机构信息

Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD, 20892, United States.

出版信息

Expert Rev Precis Med Drug Dev. 2024;9(1):3-16. doi: 10.1080/23808993.2024.2325936. Epub 2024 Mar 11.

Abstract

INTRODUCTION

Patient selection remains challenging as the clinical use of re-irradiation (re-RT) increases. Re-RT data is limited to retrospective studies and small prospective single-institution reports, resulting in small, heterogenous data sets. Validated prognostic and predictive biomarkers are derived from large-volume studies with long-term follow-up. This review aims to examine existing re-RT publications and available data sets and discuss strategies using artificial intelligence (AI) to approach small data sets to optimize the use of re-RT data.

METHODS

Re-RT publications were identified where associated public data was present. The existing literature on small data sets to identify biomarkers was also explored.

RESULTS

Publications with associated public data were identified, with glioma and nasopharyngeal cancers emerging as the most common tumor sites where the use of re-RT was the primary management approach. Existing and emerging AI strategies have been used to approach small data sets including data generation, augmentation, discovery, and transfer learning.

CONCLUSIONS

Further data is needed to generate adaptive frameworks, improve the collection of specimens for molecular analysis, and improve the interpretability of results in re-RT data.

摘要

引言

随着再程放疗(re-RT)临床应用的增加,患者选择仍然具有挑战性。再程放疗数据仅限于回顾性研究和小型前瞻性单机构报告,导致数据集规模小且异质性大。经过验证的预后和预测生物标志物来自长期随访的大规模研究。本综述旨在审视现有的再程放疗出版物和可用数据集,并讨论使用人工智能(AI)处理小数据集以优化再程放疗数据使用的策略。

方法

确定了存在相关公共数据的再程放疗出版物。还探索了关于识别生物标志物的小数据集的现有文献。

结果

识别出了具有相关公共数据的出版物,其中胶质瘤和鼻咽癌成为使用再程放疗作为主要治疗方法的最常见肿瘤部位。现有和新兴的人工智能策略已被用于处理小数据集,包括数据生成、增强、发现和迁移学习。

结论

需要更多数据来生成适应性框架,改善用于分子分析的标本收集,并提高再程放疗数据结果的可解释性。

相似文献

2
Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review.人工智能将彻底改变炎症性肠病临床试验:全面综述。
Therap Adv Gastroenterol. 2025 Feb 23;18:17562848251321915. doi: 10.1177/17562848251321915. eCollection 2025.

本文引用的文献

5
Artificial intelligence in pancreatic cancer.胰腺癌中的人工智能。
Theranostics. 2022 Oct 3;12(16):6931-6954. doi: 10.7150/thno.77949. eCollection 2022.
6
Radiomics in neuro-oncological clinical trials.神经肿瘤学临床试验中的放射组学。
Lancet Digit Health. 2022 Nov;4(11):e841-e849. doi: 10.1016/S2589-7500(22)00144-3. Epub 2022 Sep 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验